4th Annual RAS Targeted Drug Development Summit
Evvnt Promotion / evvnt
Archivo
26.09.2022 - 28.09.2022 Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
Temas de la conferencia
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Información e inscripción:
https://go.evvnt.com/1209735-2?pid=4832
Ms. Erin Thomas
Medicina General
Idioma
Inglés
Inglés
Cuota del Congreso
USD 2599.00 - USD 5398.00
USD 2599.00 - USD 5398.00
Los participantes esperaban
1000
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
